Since a range of small molecules targeting TrxG and PcG proteins have gained success in preclinical development, such as WDR5-MLL interaction antagonist OICR-9429, MENIN inhibitor MI-403, and EZH2 inhibitor EPZ-6438 (47), our data provide the rationale to test these TrxG- or PcG-targeted drugs in the treatment of HCC. The gene discussed is KMT2A; the disease is hepatocellular carcinoma.